Achieve Life Sciences Inc Net Assets
Achieve Life Sciences Inc net assets. Based on the latest financial reports, Achieve Life Sciences Inc (SP4P) has net assets worth €10.68 Million EUR (≈ $12.48 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€33.10 Million ≈ $38.70 Million USD) and total liabilities (€22.43 Million ≈ $26.22 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Achieve Life Sciences Inc to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €10.68 Million |
| % of Total Assets | 32.25% |
| Annual Growth Rate | 1.41% |
| 5-Year Change | -23.27% |
| 10-Year Change | N/A |
| Growth Volatility | 74.32 |
Net Assets of Achieve Life Sciences Inc (2016–2025)
Net assets of Achieve Life Sciences Inc from 2016 to 2025. This chart illustrates how Achieve Life Sciences Inc's net assets have evolved over time, based on quarterly financial data. See SP4P equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Achieve Life Sciences Inc (2016–2025)
The table below shows the annual net assets of Achieve Life Sciences Inc from 2016 to 2025. For live market cap and overall valuation, see SP4P market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €21.52 Million ≈ $25.16 Million |
+2.96% |
| 2024-12-31 | €20.90 Million ≈ $24.43 Million |
+1543.30% |
| 2023-12-31 | €-1.45 Million ≈ $-1.69 Million |
-117.44% |
| 2022-12-31 | €8.30 Million ≈ $9.71 Million |
-70.39% |
| 2021-12-31 | €28.04 Million ≈ $32.78 Million |
-24.79% |
| 2020-12-31 | €37.29 Million ≈ $43.59 Million |
+106.57% |
| 2019-12-31 | €18.05 Million ≈ $21.10 Million |
+14.23% |
| 2018-12-31 | €15.80 Million ≈ $18.47 Million |
+100.56% |
| 2017-12-31 | €7.88 Million ≈ $9.21 Million |
-58.46% |
| 2016-12-31 | €18.97 Million ≈ $22.17 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Achieve Life Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25816400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Achieve Life Sciences Inc Net Assets Breakdown (December 2025)
Achieve Life Sciences Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €281.74 Million | 1309.34% |
| Total Equity | €21.52 Million | 100.00% |
Achieve Life Sciences Inc Competitors by Market Cap
The table below lists competitors of Achieve Life Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sparebank 1 Ostfold Akershus
OL:SOAG
|
$574.93 Million |
|
Bridgewater Bancshares Inc
NASDAQ:BWB
|
$574.96 Million |
|
BES Engineering Co
TW:2515
|
$574.97 Million |
|
Guangxi Nanning Waterworks Co
SHG:601368
|
$574.97 Million |
|
SeaBird Exploration Plc
OL:SBX
|
$574.77 Million |
|
Konka Group Co Ltd
SHE:000016
|
$574.73 Million |
|
Shen Zhen Bauing Construction Holding Group Co Ltd
SHE:002047
|
$574.66 Million |
|
Meridian Mining UK Societas
TO:MNO
|
$574.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Achieve Life Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 20,899,000 to 21,518,000, a change of 619,000 (3.0%).
- Net loss of 54,648,000 reduced equity.
- New share issuances of 45,142,000 increased equity.
- Other factors increased equity by 10,125,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-54.65 Million | -253.96% |
| Share Issuances | €45.14 Million | +209.79% |
| Other Changes | €10.12 Million | +47.05% |
| Total Change | €- | 2.96% |
Book Value vs Market Value Analysis
This analysis compares Achieve Life Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 14.97x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.05x to 14.97x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €131.89 | €6.05 | x |
| 2018-12-31 | €47.02 | €6.05 | x |
| 2019-12-31 | €12.24 | €6.05 | x |
| 2020-12-31 | €6.10 | €6.05 | x |
| 2021-12-31 | €2.97 | €6.05 | x |
| 2022-12-31 | €0.46 | €6.05 | x |
| 2023-12-31 | €-0.07 | €6.05 | x |
| 2024-12-31 | €0.60 | €6.05 | x |
| 2025-12-31 | €0.40 | €6.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Achieve Life Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -253.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.94x
- Recent ROE (-253.96%) is below the historical average (-152.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -106.13% | -397.65% | 0.18x | 1.45x | €-22.03 Million |
| 2017 | -134.32% | 0.00% | 0.00x | 1.26x | €-11.37 Million |
| 2018 | -80.29% | 0.00% | 0.00x | 1.21x | €-14.27 Million |
| 2019 | -90.83% | 0.00% | 0.00x | 1.17x | €-18.20 Million |
| 2020 | -39.51% | 0.00% | 0.00x | 1.08x | €-18.46 Million |
| 2021 | -118.22% | 0.00% | 0.00x | 1.69x | €-35.96 Million |
| 2022 | -510.06% | 0.00% | 0.00x | 3.61x | €-43.18 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | €-29.67 Million |
| 2024 | -190.57% | 0.00% | 0.00x | 1.85x | €-41.92 Million |
| 2025 | -253.96% | 0.00% | 0.00x | 1.94x | €-56.80 Million |
Industry Comparison
This section compares Achieve Life Sciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Achieve Life Sciences Inc (SP4P) | €10.68 Million | -106.13% | 2.10x | $574.89 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreement… Read more